Storia in 3 fonti

ASCO 2026: key readouts in lung cancer - Pharmaceutical Technology

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.

Raccontata da

statnews.com

pharmaceutical-technology.com

biopharmadive.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

statnews.com3 mesi fa

At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions

Leggi questa versione → originale

pharmaceutical-technology.com3 mesi fa

ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC - Pharmaceutical…

Akeso's ivonescimab bispecific achieved 34% death risk reduction in squamous NSCLC; Eli Lilly expanded Retevmo (RET TKI) to adjuvant early-stage disease. Both mark competitive reshaping of NSCLC, with Idafang projected at $11bn global sales by 2032.

Leggi questa versione → originale

Timeline cronologica

venerdì 29 maggio 2026·statnews.com
At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions
lunedì 1 giugno 2026·pharmaceutical-technology.com
ASCO 2026: key readouts in lung cancer - Pharmaceutical Technology
At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.

ASCO 2026: key readouts in lung cancer - Pharmaceutical Technology

Confronto fonti

At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer

ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC - Pharmaceutical…

Timeline cronologica

At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer

ASCO 2026: key readouts in lung cancer - Pharmaceutical Technology

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

ASCO26: Blood cancer readouts take centre stage - Pharmaceutical Technology

ASCO26: In vivo oncology approaches continue to show promise

ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC - Pharmaceutical Technology